EUVIMEDEUVIMED entdecken
Leserbrief

Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”

Yingzhe Zhang

Hepatology Research · 2026-11 · 56 (11) · 1763-1764

DOI: 10.1111/hepr.70227 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Hepatology Research, online erschienen am 24.06.2026. Verfasst von Yingzhe Zhang. Beteiligte Einrichtung: Department of Pharmacy, Shaoxing Central Hospital, Shaoxing University, Shaoxing, China. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Pharmacy, Shaoxing Central Hospital, Shaoxing University, Shaoxing, China.

Zitieren

APA

Zhang, Y. (2026). Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”. Hepatology Research, 56(11), 1763-1764. https://doi.org/10.1111/hepr.70227

Vancouver

Zhang Y. Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”. Hepatology Research. 2026;56(11):1763-1764. doi:10.1111/hepr.70227

BibTeX
@article{Zhang2026,
  author = {Zhang, Yingzhe},
  title = {Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {11},
  pages = {1763--1764},
  doi = {10.1111/hepr.70227}
}
Kostenlos starten →